It was my pleasure to participate in a panel session on “SEP Current & Proposed Regulations” last month at the George Mason University Antonin Scalia Law School Center for Intellectual Property x Innovation Policy (C-IP2) Annual Fall Conference entitled “The Importance of Exclusive Rights.” Read more
I recently had the pleasure of participating in a panel on third-party litigation funding (TPLF), which was part of the Annual Fall Conference at George Mason University’s Center for Intellectual Property x Innovation Policy.
The panel included experts from both industry and academia, highlighted the growing debate around TPLF, and crystallized why this financing tool is so crucial for America’s innovators and inventors. Read more
By Emily Michiko Morris & Douglas Park
The high cost of some pharmaceuticals is a complex issue, but the Federal Trade Commission’s (FTC’s) most recent criticism of pharmaceutical patents’ role is misguided. The FTC has criticized the listing of drug product device patents in the FDA’s “Orange Book,” a listing of patents related to various FDA-approved drug products. Read more
CIP2 congratulates the Arts & Entertainment Advocacy Clinic at Scalia Law, led by Professor Sandra Aistars, and Student Advocate Natalie Nachman, and supported by Counsel of Record Matt Hersh of Mestaz Law, for filing a powerful amicus brief on behalf of three Tattoo Artists in the 9th Circuit Court of Appeals this week in Sedlik v.
Greetings from C-IP2 Interim Executive Director Joshua A. KreshAs we transition into the fall season, I am delighted to share that we have had a productive summer and are looking forward to an eventful fall and winter. The past months have been marked by significant achievements and exciting developments, building upon the robust foundation we laid earlier this year. Read more
The following post was originally published on the Patently-O blog and is cross-posted here with permission from both Patently-O and the author.
Senators aim to rein in digital replicas with the “NO FAKES” Act which proposes a limited federal right to control one’s likeness using some DMCA-like notice-and-takedown elements. Read more
By Molly Stech*
* The blog post below and the law review article it links to are the individual thoughts and views of the author and should not be attributed to any entity with which she is currently or has been affiliated. Read more
Greetings from C-IP2 Interim Executive Director Joshua A. KreshI am pleased to report that we have had a productive spring and are working on several items for this summer and fall. Since our last report, we published several policy briefs on pending legislation, held our launch event for our 5G book, welcomed our new Edison Fellows for their first meeting (and saw several publications from earlier Fellows), and ran the 2024 WIPO-U.S. Read more
By Emily Michiko Morris and Joshua Kresh
Executive summary: Many critics of pharmaceutical companies argue that they abuse the patent system through “evergreening” or “thickets” to increase the amount of time they can avoid generic competition and keep drug prices high. Read more
The following post comes from Jack Ring, a 3L at Scalia Law and a Research Assistant at C-IP2.
On April 15, 2024, C-IP2 scholars and contributors to 5G and Beyond: Intellectual Property and Competition Policy in the Internet of Things met for a live-streamed book launch event. Read more
